August 26 2020 –  Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF)  is a signal protein produced by cells that stimulates the formation of blood vessels. VEGF is a sub-family of growth factors, the platelet-derived growth factor …

Increased Risk Of Aneurysms And Artery Dissections With VEGF Inhibitors Read more »

Tagged with: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

February 11, 2018 – Long after cancer treatment ends, many patients continue to deal with one particular symptom that refuses to go away: fatigue. In a new study, researchers have found that the power of placebos, even when fully disclosed to …

Placebo: A veritable treatment option Read more »

Tagged with: , , , , , , , , ,

January 29, 2018 – Gastroenteropancreatic neuroendocrine tumors (GEP-NET)s are a rare group of cancers with limited treatment options that affects primarily the pancreas or gastrointestinal tract of patients.   The American Food & Drug Administration (FDA) just approved Lutetium (Lu …

Lutetium 177 dotatate (Lutathera): A treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Read more »

Tagged with: , , , , , , ,

Dezember 21, 2017 – Erdheim–Chester disease ((ECD), also known as Erdheim–Chester syndrome or polyostotic sclerosing histiocytosis) is a form of a bone marrow borne blood cancer. It is a rare disease characterized by the abnormal multiplication of a specific type …

Vemurafenib (Zelboraf) for BRAF V600E positive Erdheim-Chester Disease (ECD) Read more »

Tagged with: , , , , , , , , ,

October 12, 2014 – The U.S. Food and Drug Administration, on October 10,  approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy. Akynzeo is a fixed combination capsule comprised of two drugs. Oral palonosetron approved …

Netupitant/Palonosetron [Akynzeo] for nausea and vomiting associated with cancer chemotherapy approved in the US Read more »

Tagged with: , , , , , ,

November 3, 2009 – As we learn from it’s todays announcement, FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF …

Boxed Warning Updated: TNF Blockers and Cancer Risks in Children Read more »

Tagged with: , , , , , , , , ,